TD Cowen raises Regeneron's PT on huge potential for myasthenia gravis drug

Regeneron Pharmaceuticals

23/04/2026 12:18

** Brokerage TD Cowen raises price target on Regeneron Pharmaceuticals REGN.O to $960 from $800; reiterates 'buy'

** Brokerage says the drugmaker's C5 siRNA drug cemdi has best-in-class potential in generalized myasthenia gravis, a rare disease that causes muscle weakness due to faulty nerve-muscle signaling

** Brokerage says late-stage data showed cemdi, dosed once every three months via injection under the skin, reduced daily symptom scores more than approved C5 inhibitors and rival immune-targeting drugs

** Says co plans to seek U.S. approval for cemdi in gMG with a priority review, targeting a decision in the second half of 2026

** Adds cemdi and Regeneron's broader C5 program could unlock a multi-billion-dollar opportunity across gMG, a rare blood disorder and an eye disease as systemic C5 inhibition expands use

** As of last close, stock down ~3% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))